Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms

About this update from Virbac Sa

[{"type":"image","alt":"Virbac","displaySize":"","headline":null,"caption":"Virbac","className":"","disableSlideshowImg":false,"size":{"original":{"width":99,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/7ae5e0df9199b70d3cda6ff19e657ce8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RwbgVx.AZdZxIOLB0rj58A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTU2/https://media.zenfs.com/en/globenewswire.com/7ae5e0df9199b70d3cda6ff19e657ce8","width":99,"height":50}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-quarter 2026 revenue reached €384m : ","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"+7.7% at constant exchange rate and scope (CERS) vs Q1 2025","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"+2.2% at actual rates impacted by significant currency headwinds","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":123,"olType":false}]},{"val":[{"type":"text","content":"Balanced growth in both segments : companion animal +9.9% and farm animal +8.4% with a strong contribution from our Supercharge platforms (excl. Thyronorm) with an increase of around +15% at CERS.","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"Solid volume/mix effect of ~+6%, completed by price increase of ~+2%","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Excellent Q1 2026 performance driven by exceptional growth in North America (+20.7% at CERS), solid expansion in the International region (+9.1%), and sustained positive momentum in Europe (+2.0%).","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Thyronorm acquisition contributed approximately 1ppt to our overall growth in the first quarter.","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 guidance unchanged: including Thyronorm acquisition impact revenue growth expected to be between 5.5% and 7.5% at constant rates and scope. Adjusted recurring operating income1 expected around 17%","length":201,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":923,"olType":false},{"type":"text","content":"Paul Martingell, Chief Executive Officer statement","length":50,"tagName":"p"},{"type":"text","content":"“Our strong start to the year underscores the competitive strength of our model, driven by a highly balanced performance across both our Companion and F...

More updates from Virbac Sa